Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized heparin in mainly moderate COVID-19
PACTR202007606032743Recruiting
- Sponsor
- Dr Tarek Ismail
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of care with Standard of care plus nebulized heparin (2 arms). Primary endpoint: Average daily PaO2/FiO2 ratio on room air over 7 days. Started Jun 2020; status: recruiting.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202007606032743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007606032743.